Citations

Clear

426 citation(s) found for "ST, Reza".

Metastatic Neuroendocrine Tumor with Cardiac Involvement Utilizing Multi-Modality Imaging
Arsanjani, Reza , Agasthi, Pradyumna , Ahn, Daniel H. , Mookadam, Farouk , Yang, Ming , Yang, Ming , Arsanjani, Reza

Mayo Clinic

Korean Circulation Journal | April 8, 2019 | Volume: 49 | Issue: 6 | Pages: 557

10.4070/kcj.2018.0367 | PMID 31074227 Get It

Impact of Balloon Guide Catheter Use on Clinical and Angiographic Outcomes in the STRATIS Stroke Thrombectomy Registry
Zaidat, Osama O. , Mueller‐Kronast, Nils , Hassan, Ameer E , Jadhav, Ashutosh P. , Froehler, Michael T. , Aziz‐Sultan, Mohammad Ali , Klucznik, Richard , Hellinger, Frank R, Yavagal, Dileep R. , Yao, Tom L., Gupta, Rishi , Martin, Coleman, Bozorgchami, Hormozd, Kaushal, Ritesh , Gandhi, Ravi H. , Peterson, Eric C. , Given, Curtis A., Mehta, Brijesh , Deshmukh, Vivek R., Starkman, Sidney , Linfante, Italo , McPherson, Scott H., Kvamme, Peter , Grobelny, Thomas, Hussain, Muhammad Shazam , Thacker, Ike, Vora, Nirav , Monteith, Stephen J., Ecker, Robert D., Schirmer, Clemens M. , Sauvageau, Eric , Chebl, Alex , Derdeyn, Colin P. , Maidan, Lucian, Badruddin, Aamir , Siddiqui, Adnan H. , Dumont, Travis M., Alhajeri, Abdulnasser, Taqi, Muhammad , Asi, Khaled, Carpenter, Jeffrey , Boulos, Alan S. , Jindal, Gaurav , Puri, Ajit S , Robinson, David , Kallmes, David F. , Baxter, Blaise, Jumaa, Mouhammad , Sunenshine, Peter, Majjhoo, Aniel, English, Joey , Fessler, Richard D., Delgado-Almandoz, Josser, Martin, Jerry C., Liebeskind, David S. , Investigators, on behalf of the STRATIS, Liebeskind, David S. , Siddiqui, Adnan H , Hassan, Ameer E , Schirmer, Clemens M , Jadhav, Ashutosh P , Haussen, Diogo C , Jahan, Reza , Saver, Jeffrey L. , Nogueira, Raul G. , Dashti, Shervin R , Chen, Peng R , Chitale, Rohan V , Deshaies, Eric Michael , Suzuki, Shuichi , Investigators, on behalf of the STRATIS, Derdeyn, Colin P

Mayo Clinic

Stroke | February 19, 2019 | Volume: 50 | Issue: 3 | Pages: 697-704

10.1161/strokeaha.118.021126 | PMID 30776994 Get It

Background and Purpose— Mechanical thrombectomy has been shown to improve clinical outcomes in patients with acute ischemic stroke. However, the impact of balloon guide catheter (BGC) use is not well established. Methods— STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter study of patients with large vessel occlusion treated with the Solitaire stent retriever as first-line therapy. In this study, an independent core laboratory, blinded to the clinical outcomes, reviewed all procedures and angiographic data to classify procedural technique, target clot location, recanalization after each pass, and determine the number of stent retriever passes. The primary clinical end point was functional independence (modified Rankin Scale, 0–2) at 3 months as determined on-site, and the angiographic end point was first-pass effect (FPE) success rate from a single device attempt (modified Thrombolysis in Cerebral Infarction, ≥2c) as determined by a core laboratory. Achieving modified FPE (modified Thrombolysis in Cerebral Infarction, ≥2b) was also assessed. Comparisons of clinical outcomes were made between groups and adjusted for baseline and procedural characteristics. All participating centers received institutional review board approval from their respective institutions. Results— Adjunctive technique groups included BGC (n=445), distal access catheter (n=238), and conventional guide catheter (n=62). The BGC group had a higher rate of FPE following first pass (212/443 [48%]) versus conventional guide catheter (16/62 [26%]; P =0.001) and distal access catheter (83/235 [35%]; P =0.002). Similarly, the BGC group had a higher rate of modified FPE (294/443 [66%]) versus conventional guide catheter (26/62 [42%]; P <0.001) and distal access catheter (129/234 [55%]; P =0.003). The BGC group achieved the highest rate of functional independence (253/415 [61%]) versus conventional guide catheter (23/55 [42%]; P =0.007) and distal access catheter (113/218 [52%]; P =0.027). Final revascularization and mortality rates did not differ across the groups. Conclusions— BGC use was an independent predictor of FPE, modified FPE, and functional independence, suggesting that its routine use may improve the rates of early revascularization success and good clinical outcomes. Clinical Trial Registration— URL: https://www.clinicaltrials.gov . Unique identifier: NCT02239640.
Are we there yet with patent foramen ovale closure for secondary prevention in cryptogenic stroke? A systematic review and meta-analysis of randomized trials
Agasthi, Pradyumna , Kolla, Kantha R. , Yerasi, Charan , Tullah, Sibghat, Pulivarthi, Venkata Siva Krishna Kumar, Louka, Boshra, Mookadam, Farouk , Fortuin, F. David , Kolla, Kantha Ratnam, Pulivarthi, Venkata Siva, Arsanjani, Reza , Yang, Eric H.

Mayo Clinic

SAGE Open Medicine | February 5, 2019 | Volume: 7 | Issue: No issue available | Pages: No page available

10.1177/2050312119828261 | PMID 30783525 Get It

Background: We performed a meta-analysis to evaluate the benefit of patent foramen ovale closure in stroke prevention. Methods: We searched Medline/PubMed, EMBASE, Web of Science and Cochrane central database for randomized control trials assessing the incidence of recurrent stroke after patent foramen ovale closure when compared to medical therapy. Pooled odds ratio and 95% confidence intervals were calculated using a random effects model. The heterogeneity among studies was tested using the χ 2 test and inconsistency was quantified using the I 2 statistic. Results: Our search strategy yielded 71 articles. We included five studies with a total of 3440 patients. Median age in the device group was 45 (43, 5.5) years and in the medical group was 45 (44.5, 46) years; 52% were male, 27.7% of patients had an atrial septal aneurysm, 25% had hypertension, and 20.5% had diabetes mellitus. The median follow-up time was 44 (34.5–50) months. The pooled odds ratio of recurrent stroke, transient ischemic attack and composite end point of stroke + transient ischemic attack + peripheral embolism in the patent foramen ovale closure versus medical therapy group were 0.4 (95% confidence interval 0.25–0.63, I 2 = 57.5%), 0.93 (95% confidence interval 0.61–1.42, I 2 = 0%), and 0.6 (95% confidence interval 0.44–0.82, I 2 = 0%), respectively. The incidence of atrial fibrillation was found to be significantly higher in the patent foramen ovale closure group with odds ratio of 6 (95% confidence interval 3.13–11.4, I 2 = 33.5%). On subgroup analysis, patent foramen ovale closure appeared to benefit males and patients with a large shunt. Number needed to treat to prevent one recurrent stroke with patent foramen ovale closure is 42. Number needed to harm to cause one atrial fibrillation with patent foramen ovale closure is 39. Conclusion: This meta-analysis of randomized trials concludes that percutaneous patent foramen ovale closure is effective in recurrent stroke prevention especially in males and in those with a large shunt.
Outcome measures for pediatric laryngotracheal reconstruction: International consensus statement
Balakrishnan, Karthik , Sidell, Douglas R. , Bellia‐Munzon, Gaston F., Boesch, R. Paul , Bromwich, Matthew, Cofer, Shelagh A. , Daines, Cori , Alarcón, Alessandro de , Garabédian, N , Ida, Jonathan B., Leboulanger, Nicolas , Manning, Peter B., Mehta, Deepak, Monnier, Philippe, Myer, Charles M. , Prager, Jeremy D. , Propst, Evan J. , Rahbar, Reza , Russell, John , Rutter, Michael J. , Thierry, Briac , Thompson, Dana M. , Torre, Michele , Varela, Patricio, Vijayasekaran, Shyan , White, David R. , Wineland, Andre , Wood, Robert E. , Wootten, Christopher T. , Zur, Karen B. , Cotton, Robin T., Sidell, Douglas R. , Hart, Catherine K , Leboulanger, Nicolas , Prager, Jeremy D , Zur, Karen , Sidell, Douglas R , Bauman, Nancy M. , Bellía-Munzón, Gastón , Hart, Catherine K. , Preciado, Diego A.

Mayo Clinic

The Laryngoscope | August 28, 2018 | Volume: 129 | Issue: 1 | Pages: 244-255

10.1002/lary.27445 | PMID 30152166 Get It

ObjectivesDevelop multidisciplinary and international consensus on patient, disease, procedural, and perioperative factors, as well as key outcome measures and complications, to be reported for pediatric airway reconstruction studies.MethodsStandard Delphi methods were applied. Participants proposed items in three categories: 1) patient/disease characteristics, 2) procedural/intraoperative/perioperative factors, and 3) outcome measures and complications. Both general and anatomic site‐specific measures were elicited. Participants also suggested specific operations to be encompassed by this project. We then used iterative ranking and review to develop consensus lists via a priori Delphi consensus criteria.ResultsThirty‐three pediatric airway experts from eight countries in North and South America, Europe, and Australia participated, representing otolaryngology (including International Pediatric Otolaryngology Group members), pulmonology, general surgery, and cardiothoracic surgery. Consensus led to inclusion of 19 operations comprising open expansion, resection, and slide procedures of the larynx, trachea, and bronchi as well as three endoscopic procedures. Consensus was achieved on multiple patient/comorbidity (10), disease/stenosis (7), perioperative‐/intraoperative‐/procedure‐related (16) factors. Consensus was reached on multiple outcome and complication measures, both general and site‐specific (8 general, 13 supraglottic, 15 glottic, 17 subglottic, 8 cervical tracheal, 12 thoracic tracheal). The group was able to clarify how each outcome should be measured, with specific instruments defined where applicable.ConclusionThis consensus statement provides a framework to communicate results consistently and reproducibly, facilitating meta‐analyses, quality improvement, transfer of information, and surgeon self‐assessment. It also clarifies expert opinion on which patient, disease, procedural, and outcome measures may be important to consider in any pediatric airway reconstruction patient.Level of Evidence5 Laryngoscope, 129:244–255, 2019
Cardiopulmonary Function in Thoracic Wall Deformities: What Do We Really Know?
Velazco, Cristine S. , Pulivarthi, Venkata, Arsanjani, Reza , Obermeyer, Robert J., Jaroszewski, Dawn E. , Pulivarthi, Venkata Siva Krishna Kumar, Arsanjani, Reza

Mayo Clinic

European Journal of Pediatric Surgery | August 13, 2018 | Volume: 28 | Issue: 04 | Pages: 327-346

10.1055/s-0038-1668130 | PMID 30103240 Get It

AbstractPatients with pectus excavatum (PE) frequently present with complaints of exercise intolerance and cardiopulmonary symptoms. There continues to be controversy regarding the physiologic benefits of repair. The aim of this review is to summarize and discuss recent data regarding the cardiopulmonary effects of PE deformity and the evidence for improvement obtained after surgical repair including (1) a greater efficiency of breathing (chest wall mechanics), (2) improvement in pulmonary restrictive deficits, (3) an increase in cardiac chamber size and output, with improved cardiac strain and strain rate, and (4) improvement in exercise capacity.
A comprehensive evaluation of the genetic architecture of sudden cardiac arrest
Ashar, Foram N., Albert, Christine M. , Newton‐Cheh, Christopher , Brody, Jennifer A. , Müller‐Nurasyid, Martina , Moes, Anna, Huikuri, Heikki V. , Junttila, Juhani , Goyette, Philippe, Pazoki, Raha , Tanck, Michael W.T. , Blom, Marieke T. , Jabbari, Reza , Glinge, Charlotte , Tragante, Vinicius , Escher, Stefan Andersson, Chakravarti, Aravinda , Ehret, Georg , Li, Man , Prineas, Ronald J. , Franco, Oscar H. , Lumley, Thomas, Dumas, Florence , McKnight, Barbara, Rotter, Jerome I. , Heckbert, Susan R. , O’Donnell, Christopher J., VanDenburgh, Martin, Uitterlinden, André G. , Hofman, Albert , Stricker, Bruno H. , Bakker, Paul I. W. de , Franks, Paul W. , Jansson, Jan‐Håkan , Asselbergs, Folkert W. , Maleszewski, Joseph J. , Tfelt‐Hansen, Jacob , Kolodgie, Frank D. , Wilde, Arthur A.M. , Bezzina, Connie R. , Eijgelsheim, Mark, Rioux, John D. , Jouven, Xavier , Arking, Dan E. , Sotoodehnia, Nona , Tanck, Michael , Tfelt-Hansen, Jacob , Rotter, Jerome I , Brody, Jennifer A , Bezzina, Connie R , Mitchell, Rebecca N, Meitinger, Thomas , Mak, Angel C. Y. , Pulit, Sara L. , Zhao, Xiaoqing , Havulinna, Aki Samuli , Coresh, Josef , Kwok, Pui–Yan , Lemaître, Rozenn N. , Hwang, Shih‐Jen , Tardif, Jean‐Claude , Halushka, Marc K. , Engstrøm, Thomas , Salomaa, Veikko , Virmani, Renu , Tan, Hanno L. , Kääb, Stefan , Psaty, Bruce M. , Siscovick, David S. , Rioux, John D , Albert, Christine M.

Mayo Clinic

European Heart Journal | July 20, 2018 | Volume: 39 | Issue: 44 | Pages: 3961-3969

10.1093/eurheartj/ehy474 | PMID 30169657 Get It

DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition
Hubers, Scott , Wilson, Jessica R. , Nian, Hui , Grouzmann, Eric , Eugster, Philippe J. , Shibao, Cyndya A. , Billings, Frederic T. , Kerman, Scott Reza Jafarian , Hubers, Scott A, Kerman, Scott Jafarian , Eugster, Philippe J , Yu, Chang , Shibao, Cyndya A , Brown, Nancy J.

Mayo Clinic

Hypertension | July 9, 2018 | Volume: 72 | Issue: 3 | Pages: 712-719

10.1161/hypertensionaha.118.11498 | PMID 29987109 Get It

DPP (dipeptidyl peptidase)-4 inhibitors are antidiabetic drugs that may increase heart failure in high-risk patients. NPY (neuropeptide Y) is coreleased with norepinephrine, causes vasoconstriction via the Y1 receptor, and is degraded by DPP4 to NPY (3–36) in vitro. NPY (3–36) decreases release of norepinephrine via the Y2 receptor. We tested the hypothesis that DPP4 inhibition would potentiate the vasoconstrictor effect of NPY. Eighteen nonsmokers (12 healthy controls and 6 with type 2 diabetes mellitus) participated in 1 of 2 randomized, double-blind, placebo-controlled crossover studies. First, subjects were randomized to order of treatment with sitagliptin 100 mg/d versus placebo for 7 days separated by 4-week washout. On the last day of treatment, NPY was infused by brachial artery and forearm blood flow was measured using plethysmography. Blood samples were collected after each dose. NPY infusions were repeated after 90-minute washout and intra-arterial enalaprilat. Second, 5 healthy subjects were randomized to crossover treatment with sitagliptin 100 mg/d plus valsartan 160 mg/d versus placebo plus valsartan. NPY infusions were performed on the seventh day of treatment. NPY caused dose-dependent vasoconstriction. During enalaprilat, sitagliptin significantly potentiated NPY-induced vasoconstriction in controls and diabetics ( P ≤0.02 for forearm blood flow in either group). Baseline norepinephrine release was increased during sitagliptin and enalaprilat, but not further by NPY. Sitagliptin increased the ratio of NPY to NPY (3–36). During valsartan, sitagliptin also significantly potentiated NPY-induced vasoconstriction ( P =0.009 for forearm blood flow). Potentiation of endogenous NPY could contribute to cardiovascular effects of DPP4 inhibitors in patients taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
Interhospital Transfer Before Thrombectomy Is Associated With Delayed Treatment and Worse Outcome in the STRATIS Registry (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke)
Froehler, Michael T. , Zaidat, Osama O., Aziz‐Sultan, Mohammad Ali , Klucznik, Richard , Hellinger, Frank R, Yavagal, Dileep R. , Yao, Tom L., Liebeskind, David S, Jadhav, Ashutosh P. , Gupta, Rishi , Hassan, Ameer E , Martin, Coleman, Bozorgchami, Hormozd, Kaushal, Ritesh , Gandhi, Ravi H. , Peterson, Eric C. , Given, Curtis A., Mehta, Brijesh , Deshmukh, Vivek R., Starkman, Sidney , Linfante, Italo , McPherson, Scott H., Kvamme, Peter , Grobelny, Thomas, Hussain, Muhammad Shazam , Thacker, Ike, Vora, Nirav , Monteith, Stephen J., Ecker, Robert D., Schirmer, Clemens M. , Sauvageau, Eric , Abou‐Chebl, Alex, Derdeyn, Colin P. , Maidan, Lucian, Badruddin, Aamir , Siddiqui, Adnan H. , Dumont, Travis M., Alhajeri, Abdulnasser, Taqi, Muhammad , Asi, Khaled, Carpenter, Jeffrey , Boulos, Alan S. , Jindal, Gaurav , Puri, Ajit S , Robinson, David , Kallmes, David F. , Baxter, Blaise, Jumaa, Mouhammad , Sunenshine, Peter, Majjhoo, Aniel, English, Joey , Fessler, Richard D., Martin, Jerry C., Mueller‐Kronast, Nils , Liebeskind, David S. , Liebeskind, David S. , Siddiqui, Adnan H , Hassan, Ameer E , Schirmer, Clemens M , Saver, Jeffrey L. , Jahan, Reza , Haussen, Diogo C , Nogueira, Raul G. , Dashti, Shervin R , Chen, Peng R , Chitale, Rohan V , Deshaies, Eric Michael , Suzuki, Shuichi , Almandoz, Josser E Delgado , Jadhav, Ashutosh P , Derdeyn, Colin P

Mayo Clinic

Circulation | September 25, 2017 | Volume: 136 | Issue: 24 | Pages: 2311-2321

10.1161/circulationaha.117.028920 | PMID 28943516 Get It

Background: Endovascular treatment with mechanical thrombectomy (MT) is beneficial for patients with acute stroke suffering a large-vessel occlusion, although treatment efficacy is highly time-dependent. We hypothesized that interhospital transfer to endovascular-capable centers would result in treatment delays and worse clinical outcomes compared with direct presentation. Methods: STRATIS (Systematic Evaluation of Patients Treated With Neurothrombectomy Devices for Acute Ischemic Stroke) was a prospective, multicenter, observational, single-arm study of real-world MT for acute stroke because of anterior-circulation large-vessel occlusion performed at 55 sites over 2 years, including 1000 patients with severe stroke and treated within 8 hours. Patients underwent MT with or without intravenous tissue plasminogen activator and were admitted to endovascular-capable centers via either interhospital transfer or direct presentation. The primary clinical outcome was functional independence (modified Rankin Score 0–2) at 90 days. We assessed (1) real-world time metrics of stroke care delivery, (2) outcome differences between direct and transfer patients undergoing MT, and (3) the potential impact of local hospital bypass. Results: A total of 984 patients were analyzed. Median onset-to-revascularization time was 202.0 minutes for direct versus 311.5 minutes for transfer patients ( P <0.001). Clinical outcomes were better in the direct group, with 60.0% (299/498) achieving functional independence compared with 52.2% (213/408) in the transfer group (odds ratio, 1.38; 95% confidence interval, 1.06–1.79; P =0.02). Likewise, excellent outcome (modified Rankin Score 0–1) was achieved in 47.4% (236/498) of direct patients versus 38.0% (155/408) of transfer patients (odds ratio, 1.47; 95% confidence interval, 1.13–1.92; P =0.005). Mortality did not differ between the 2 groups (15.1% for direct, 13.7% for transfer; P =0.55). Intravenous tissue plasminogen activator did not impact outcomes. Hypothetical bypass modeling for all transferred patients suggested that intravenous tissue plasminogen activator would be delayed by 12 minutes, but MT would be performed 91 minutes sooner if patients were routed directly to endovascular-capable centers. If bypass is limited to a 20-mile radius from onset, then intravenous tissue plasminogen activator would be delayed by 7 minutes and MT performed 94 minutes earlier. Conclusions: In this large, real-world study, interhospital transfer was associated with significant treatment delays and lower chance of good outcome. Strategies to facilitate more rapid identification of large-vessel occlusion and direct routing to endovascular-capable centers for patients with severe stroke may improve outcomes. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02239640.
Ileal Conduit Urinary Diversion in Children
Malek, Reza S., Burke, Edmund C., DeWeerd, James H.

Mayo Clinic

Journal of Urology | July 10, 2017 | Volume: 105 | Issue: 6 | Pages: 892-900

10.1016/s0022-5347(17)61655-0 | PMID 5091722 Get It

Crossed, Fused, Renal Ectopia with an Ectopic Ureterocele
Malek, Reza S., Utz, David C.

Mayo Clinic

Journal of Urology | July 10, 2017 | Volume: 104 | Issue: 5 | Pages: 665-667

10.1016/s0022-5347(17)61806-8 | PMID 5486846 Get It